Measurement of Plasma Concentration of Gemcitabine and Its Metabolite dFdU in Hemodialysis Patients with Advanced Urothelial Cancer

Abstract

According to the previous information, no dose modification of gemcitabine may be required for patients with renal impairment or hemodialysis. However, gemcitabine should be given with caution because only limited information is available, and the clinical effect of sustained and/or accumulated dFdU is unknown.